|
1
|
Sinclair R: Male pattern androgenetic
alopecia. BMJ. 317:865–869. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cash TF: The psychology of hair loss and
its implications for patient care. Clin Dermatol. 19:161–166. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Whiting DA: Possible mechanisms of
miniaturization during androgenetic alopecia or pattern hair loss.
J Am Acad Dermatol. 45(Suppl 3): S81–S86. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Urysiak-Czubatka I, Kmieć ML and
Broniarczyk-Dyła G: Assessment of the usefulness of
dihydrotestosterone in the diagnostics of patients with
androgenetic alopecia. Postepy Dermatol Alergol. 31:207–215. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aggarwal S, Thareja S, Verma A, Bhardwaj
TR and Kumar M: An overview on 5alpha-reductase inhibitors.
Steroids. 75:109–153. 2010. View Article : Google Scholar
|
|
6
|
Azzouni F, Godoy A, Li Y and Mohler J: The
5 alpha-reductase isozyme family: A review of basic biology and
their role in human diseases. Adv Urol. 2012:5301212012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McConnell JD, Wilson JD, George FW, Geller
J, Pappas F and Stoner E: Finasteride, an inhibitor of 5
alpha-reductase, suppresses prostatic dihydrotestosterone in men
with benign prostatic hyperplasia. J Clin Endocrinol Metab.
74:505–508. 1992.PubMed/NCBI
|
|
8
|
Gormley GJ, Stoner E, Bruskewitz RC,
Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J,
Bracken BR, Tenover JS, et al: The effect of finasteride in men
with benign prostatic hyperplasia. The Finasteride Study Group. N
Engl J Med. 327:1185–1191. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drake L, Hordinsky M, Fiedler V, Swinehart
J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C,
Whiting D, et al: The effects of finasteride on scalp skin and
serum androgen levels in men with androgenetic alopecia. J Am Acad
Dermatol. 41:550–554. 1999.PubMed/NCBI
|
|
10
|
Kaufman KD, Olsen EA, Whiting D, Savin R,
DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL,
Hordinsky M, et al: Finasteride in the treatment of men with
androgenetic alopecia. Finasteride Male Pattern Hair Loss Study
Group. J Am Acad Dermatol. 39:578–589. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Finasteride Male Pattern Hair Loss Study
Group: Long-term (5-year) multinational experience with finasteride
1 mg in the treatment of men with androgenetic alopecia. Eur J
Dermatol. 12:38–49. 2002.PubMed/NCBI
|
|
12
|
Whiting DA, Olsen EA, Savin R, Halper L,
Rodgers A, Wang L, Hustad C and Palmisano J; Male Pattern HairLoss
Study Group: Efficacy and tolerability of finasteride 1 mg in men
aged 41 to 60 years with male pattern hair loss. Eur J Dermatol.
13:150–160. 2003.PubMed/NCBI
|
|
13
|
Mella JM, Perret MC, Manzotti M, Catalano
HN and Guyatt G: Efficacy and safety of finasteride therapy for
androgenetic alopecia: A systematic review. Arch Dermatol.
146:1141–1150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng D, Huang K, Liu Y and Liu S:
Preparation of novel polymeric microspheres for controlled release
of finasteride. Int J Pharm. 342:82–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caon T, Porto LC, Granada A, Tagliari MP,
Silva MA, Simões CM, Borsali R and Soldi V: Chitosan-decorated
polystyrene-b-poly(acrylic acid) polymersomes as novel carriers for
topical delivery of finasteride. Eur J Pharm Sci. 52:165–172. 2014.
View Article : Google Scholar
|
|
16
|
Freiberg S and Zhu X: Polymer microspheres
for controlled drug release. Int J Pharm. 282:1–18. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nojehdehian H and Ekrami M: Loading of
gentamicin sulfate into poly (lactic-co-glycolic acid)
biodegradable microspheres. Shahid Beheshti University. J Dent Sch.
33:145–151. 2015.
|
|
18
|
Sinha V, Bansal K, Kaushik R, Kumria R and
Trehan A: Poly-ϵ-caprolactone microspheres and nanospheres: An
overview. Int J Pharma. 278:1–23. 2004. View Article : Google Scholar
|
|
19
|
Burns SA, Hard R, Hicks WL Jr, Bright FV,
Cohan D, Sigurdson L and Gardella JA Jr: Determining the protein
drug release characteristics and cell adhesion to a PLLA or PLGA
biodegradable polymer membrane. J Biomed Mater Res A. 94:27–37.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Danhier F, Ansorena E, Silva JM, Coco R,
Le Breton A and Préat V: PLGA-based nanoparticles: An overview of
biomedical applications. J Control Release. 161:505–522. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Corrigan OI and Li X: Quantifying drug
release from PLGA nanoparticulates. Eur J Pharm Sci. 37:477–485.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mu L and Feng S: A novel controlled
release formulation for the anticancer drug paclitaxel (Taxol):
PLGA nanoparticles containing vitamin E TPGS. J Control Release.
86:33–48. 2003. View Article : Google Scholar
|
|
23
|
Wang ZD, Feng Y, Ma LY, Li X, Ding WF and
Chen XM: Hair growth promoting effect of white wax and policosanol
from white wax on the mouse model of testosterone-induced hair
loss. Biomed Pharmacother. 89:438–446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Kim YJ, Choi MJ, Bak DH, Lee BC, Ko EJ,
Ahn GR, Ahn SW, Kim MJ, Na J and Kim BJ: Topical administration of
EGF suppresses immune response and protects skin barrier in
DNCB-induced atopic dermatitis in NC/Nga mice. Sci Rep.
8:118952018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hibino T and Nishiyama T: Role of
TGF-beta2 in the human hair cycle. J Dermatol Sci. 35:9–18. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen W, Zouboulis CC and Orfanos CE: The
5-alpha reductase system and its inhibitors. Recent development and
its perspective in treating androgen-dependent skin disorders.
Dermatology. 193:177–184. 1996. View Article : Google Scholar
|
|
28
|
Thornton MJ, Messenger AG, Elliott K and
Randall VA: Effect of androgens on the growth of cultured human
dermal papilla cells derived from beard and scalp hair follicles. J
Invest Dermatol. 97:345–348. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato A and Takeda A: Evaluation of
efficacy and safety of finasteride 1 mg in 3,177 Japanese men with
androgenetic alopecia. J Dermatol. 39:27–32. 2012. View Article : Google Scholar
|
|
30
|
Mysore V and Shashikumar B: Guidelines on
the use of finasteride in androgenetic alopecia. Indian J Dermatol
Venereol Leprol. 82:128–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirshburg JM, Kelsey PA, Therrien CA,
Gavino AC and Reichenberg JS: Adverse effects and safety of 5-alpha
reductase inhibitors (finasteride, dutasteride): A systematic
review. J Clin Aesthet Dermatol. 9:56–62. 2016.PubMed/NCBI
|
|
32
|
Wessells H, Roy J, Bannow J, Grayhack J,
Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S,
et al: Incidence and severity of sexual adverse experiences in
finasteride and placebo-treated men with benign prostatic
hyperplasia. Urology. 61:579–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moinpour CM, Darke AK, Donaldson GW,
Thompson IM Jr, Langley C, Ankerst DP, Patrick DL, Ware JE Jr, Ganz
PA, Shumaker SA, et al: Longitudinal analysis of sexual function
reported by men in the prostate cancer prevention trial. J Natl
Cancer Inst. 99:1025–1035. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carbone D Jr and Hodges S: Medical therapy
for benign prostatic hyperplasia: Sexual dysfunction and impact on
quality of life. Int J Impot Res. 15:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peng D, Huang K, Liu Y, Liu S, Wu H and
Xiao H: Preparation of carbon dioxide/propylene
oxide/ε-caprolactone copolymers and their drug release behaviors.
Polymer Bull. 59:117–125. 2007. View Article : Google Scholar
|
|
36
|
Ahmed OA, Hussein AK and Mady FM:
Optimisation of microstructured biodegradable finasteride
formulation for depot parenteral application. J Microencapsul.
33:229–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Clark RV, Hermann DJ, Cunningham GR,
Wilson TH, Morrill BB and Hobbs S: Marked suppression of
dihydrotestosterone in men with benign prostatic hyperplasia by
dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol
Metab. 89:2179–2184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsai TF, Choi GS, Kim BJ, Kim MB, Ng CF,
Kochhar P, Jasper S, Brotherton B, Orban B and Lulic Z: Prospective
randomized study of sexual function in men taking dutasteride for
the treatment of androgenetic alopecia. J Dermatol. 45:799–804.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fertig R, Shapiro J, Bergfeld W and Tosti
A: Investigation of the plausibility of 5-alpha-reductase inhibitor
syndrome. Skin Appendage Disord. 2:120–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wilt TJ, MacDonald R, Hagerty K,
Schellhammer P, Tacklind J, Somerfield MR and Kramer BS:
5-α-reductase inhibitors for prostate cancer chemoprevention: An
updated Cochrane systematic review. BJU Int. 106:1444–1451. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu XJ, Zhi Y, Zheng J, He P, Zhou XZ, Li
WB and Zhou ZS: Dutasteride on benign prostatic hyperplasia: A
meta-analysis on randomized clinical trials in 6,460 patients.
Urology. 83:539–543. 2014. View Article : Google Scholar
|
|
42
|
Arif T, Dorjay K, Adil M and Sami M:
Dutasteride in androge-netic alopecia: An update. Curr Clin
Pharmacol. 12:31–35. 2017. View Article : Google Scholar
|
